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eIF5A inhibition influences T 
cell dynamics in the pancreatic 
microenvironment of the humanized 
mouse model of Type 1 Diabetes
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Syed Abdul-Moiz Hasan1,2, Nancy Salim1,2, Talha Naser Jilani1,2, Raghavendra G. Mirmira  3 & 
Juan Carlos Jaume1,2
We have developed a transgenic mouse model of Type 1 Diabetes (T1D) in which human GAD65 is 
expressed in pancreatic β-cells, and human MHC-II is expressed on antigen presenting cells. Induced 
GAD65 antigen presentation activates T-cells, which initiates the downstream events leading to 
diabetes. In our humanized mice, we have shown downregulation of eukaryotic translation initiation 
factor 5 A (elF5A), expressed only in actively dividing mammalian cells. In-vivo inhibition of elF5A 
hypusination by deoxyhypusine synthase (DHS) inhibitor “GC7” was studied; DHS inhibitor alters 
the pathophysiology in our mouse model by catalyzing the crucial hypusination and the rate-limiting 
step of elF5A activation. In our mouse model, we have shown that inhibition of eIF5A resets the pro-
inflammatory bias in the pancreatic microenvironment. There was: (a) reduction of Th1/Th17 response, 
(b) an increase in Treg numbers, (c) debase in IL17 and IL21 cytokines levels in serum, (d) lowering of 
anti-GAD65 antibodies, and (e) ablation of the ER stress that improved functionality of the β-cells, but 
minimal effect on the cytotoxic CD8 T-cell (CTL) mediated response. Conclusively, immune modulation, 
in the case of T1D, may help to manipulate inflammatory responses, decreasing disease severity, 
and may help manage T1D in early stages of disease. Our study also demonstrates that without 
manipulating the CTLs mediated response extensively, it is difficult to treat T1D.
The hallmark of type 1 diabetes (T1D) is immune-mediated destruction of insulin secreting β-cells of the pancre-
atic islets of Langerhans, resulting in hyperglycemia and lifelong dependency on exogenous insulin. T1D develops 
in individuals having familial genetic susceptibility under certain intrinsic and/or environmental influences that 
are not fully understood. Immunological events, although not precisely defined, are thought to involve innate 
immune activation and adaptive T and B cell responses against various β-cell antigens1. T cells have been well 
recognized as key orchestrators of T1D in mouse models as well as in human patients. T cell dynamics in the islet 
microenvironment is characterized by T helper (Th) 1 and Th17 cell bias and/or a T-regulatory cell (Treg) defect 
that ultimately culminates into CTL mediated destruction of the β-cells2–6.
Recent studies recognize the role of Th17 cells in the mediation of T1D; coupling this information with earlier 
studies7,8 implies the dominant, yet not causal, the role of Interferon (IFN) γ and Th1 cells with the mediation 
of T1D in neonatal NOD mice9,10. Further studies indicate when IFNγ is blocked with a neutralizing antibody 
at an early stage, the disease is exacerbated11. Th17 cells are reported to be elevated in the peripheral blood and 
pancreatic lymph nodes of T1D patients as compared to healthy humans3,12,13. Both Th1 and Th17 cells seem to 
cooperate in the mediation of T1D. Th1 cells or IFNγ is often associated with an increased expression of Th17 
cells14. IL17/IFNγ receptor double-deficient mice show significantly delayed the onset of diabetes compared to 
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IL17 single knockout mice15. Another key player in the pro-inflammatory/anti-inflammatory dyad of immunity is 
the Tregs. Pancreatic Tregs in mice have been shown to be affected at both the numerical and functional levels in 
diabetic NOD mice16. Tregs in peripheral blood of human patients display increased sensitivity to apoptosis and 
are functionally defective17–21. Notably, T helper subsets are now considered more plastic than previously appre-
ciated and have demonstrated great flexibility in their differentiation options22–24. In adoptive transfer models, 
islet antigen-specific Th17 cells have been shown to convert into Th1-like cells to induce diabetes23,25. Marwaha 
et al. (2010) reported that Treg cells acquire a Th17 like phenotype in human T1D patients12. However, it is not 
yet clear if this reprogramming is required for T1D induction or if it is instead a consequence of the immune/
inflammatory response.
Nevertheless, T helper cells cannot directly interact with the β-cells due to their lack of MHC class II expression 
and are unable to cause direct cytotoxicity. They contribute to β-cell death through soluble mediators like cytokine 
and other death signals (eg IL1, TNFa, IFNγ, FASL). These inflammatory mediators initiate multiple pathways 
in β-cells, including endoplasmic reticulum (ER) stress, leading to their dysfunction and eventual death through 
apoptosis26–28. It is still debatable whether ER stress is a cause or consequence of β-cell dysfunction in T1D.
Currently, CTLs are considered prime contributors of β-cell death in T1D which is supported by numer-
ous studies involving both mice and humans6,29–31. In mouse models, efficient adoptive transfer of T1D typ-
ically requires cluster of differentiation of (CD) 8+ T cells32,33, and diabetes is prevented in MHC class I or β 
2-microglobulin deficient mice34. In humans, β-cell antigen-specific CD8 T cell expansions have been identified 
in the peripheral blood of T1D patients35,36 and CD8 T cells predominate the cellular infiltrate of the spleen from 
cadaveric T1D donors37,38.
In the present study, we tested the effect of inhibiting eukaryotic translation initiation factor 5 A (eIF5A) by 
N1-guanyl-1,7-diaminoheptane (GC7) on the T cell dynamics in the pancreas and local lymph nodes of our 
humanized mouse model of T1D. GC7 targets the deoxyhypusine synthase (DHS) enzyme which catalyzes 
hypusination of eIF5A, which is mandatory for its activity and functions39. Few studies have indicated the role 
of hypusinated eIF5A in adaptive immunity through its effect on T- and B-cell proliferation40,41, and matura-
tion of DCs42. Hypusinated eIF5A has been shown to promote cytokine-mediated β-cell dysfunction through 
post-transcriptional regulation of iNOS43. Earlier studies by our group have indicated that eIF5A inhibition delays 
the onset of T1D in our humanized mouse model44 as well as in NOD mice45. Here, we show that eIF5A inhibition 
alters T cell profiles, especially T helper subsets, in the pancreas and draining lymph nodes of the mouse model. 
We also show that eIF5A inhibition reduces the ER stress in the pancreatic microenvironment and improves the 
functionality of β-cells.
Material and Methods
Experimental Design. Two groups of our transgenic humanized mice of T1D (n = 6–8 per group) were 
used comprising of an equal number of males and females46,47. The diabetes was confirmed by hyperglycemia 
(>250 mg/dl for two consecutive days) and a positive glucose tolerance test (GTT). After the confirmation of 
diabetes, animals in one group were treated with GC7 for elF5A inhibition through intra-peritoneal route from 14 
weeks through 22 weeks of age at the dose rate of 4 mg/kg body weight for 5 days a week and served as the treat-
ment group. Animals in the other group were given placebo (normal saline) in a similar manner and served as a 
nontreated group. The animals in both the groups and their glucose levels were monitored weekly during the 
whole experiment. All the animals in both the groups were euthanized at 28 weeks of age to collect the spleen 
(SP), inguinal lymph node (IGLN), peri-pancreatic lymph node (PPLN) and pancreas (PN) (Sketch 1).
Mice. Humanized mouse model of T1D consisting of Murine MHC-class II deficient (mII_), 
HLA-DQA1*0301/DQB1*0302 (DQ8), and hGAD65 transgenic mice48 in BTBR background49 were used in this 
study46,47. DQ8 and hGAD65 homozygosity was determined as previously described44,48–50. The Institute Animals 
Care and Use Committee (IACUC), approved all animal protocols. All procedures were performed in accordance 
with the relevant guidelines and regulations from the University of Toledo.
Glucose tolerance test (GTT) and glucose-stimulated insulin secretion (GSIS). For GTT, animals 
fasted for eight hours and then given an intraperitoneal injection of 2 g glucose per kg body weight. Blood glucose 
was measured by Ascensia Breeze Glucometer (Bayer) at 0, 20, 30, 60, 90, 120, 150, 180 and 210 min. intervals via 
tail vein puncture method. In our experiment, the GTT was performed at two-time points; at the age of 12–14 
weeks (pre GC7 administration) and another at the age of 25–26 weeks (post GC7 administration). Following the 
glucose challenge, we also measured plasma insulin concentrations at 0, 10 and 30 min. using a mouse ultrasensi-
tive insulin ELISA kit (Crystal Chem, Inc., USA).
Pancreatic insulin content. Insulin was extracted from the pancreas (PN) by a standard acid-ethanol 
extraction method as described earlier51. Insulin concentration in the extract was determined using a Mouse 
Ultrasensitive Insulin ELISA kit (Crystal Chem, Inc., USA). The insulin content was standardized to the total 
protein concentration measured by Qubit Protein Assay kit (Invitrogen).
Enzyme-linked immunosorbent assays. We quantified anti-GAD65 antibodies and cytokine (IL17 and 
IL21) in the serum of the animals. Anti-GAD65 antibodies were measured with GAD65 ELISA kit (Kronus, Star, 
ID) according to the manufacturer’s instructions. IL17 and IL21 concentrations were measured using Mouse IL17 
and IL21 Platinum ELISA kit (eBioscience, San Diego, CA). At least two independent experiments in duplicated 
wells were performed, and average values for each sample were obtained for data analysis.
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Flow cytometry. The tissues were mechanically homogenized to form single cell suspensions. Cell surface 
staining was performed by incubating 5 × 106 cells with fluorochrome-conjugated antibodies against mouse CD3 
(clone 145-2C11, APC, APCCy7), CD4 (clone H129.19, PECy5), CD8 (clone 53-6.7, PECy7), CD25 (clone PC61, 
PE), (BD Biosciences, San Jose, CA) or isotype controls for 20 min. on ice. The cells were washed and fixed in 
1% paraformaldehyde. A subset of cells were permeabilized with cytofix/cytosperm fixation and permeabiliza-
tion solution (BD Biosciences). Intracellular staining was performed with fluorochrome-conjugated antibodies 
against mouse IL17 (clone 559502, PE), IFNγ (clone 554413, APC) and forkhead box P3 (FOXP3) (clone MF23, 
Alexa Fluor 488, Alexa Fluor 647) as previously described44. Hoechst 33342 (10 µg/ml) staining was performed 
to gate live cells containing 2n-4n cellular DNA. Stained cells were acquired by BD LSR II /BD FACSAria II (BD 
Biosciences) flow cytometers. The data were analyzed using FlowJo software (Tree Star Inc.)44.
Quantitative RT-PCR analysis. Total RNA was extracted from the frozen pancreatic tissue using TRIzol 
(Invitrogen) as per manufactures instructions. One µg of RNA was converted into cDNA using iScript Reverse 
Transcription kit. eIF5A and ER stress-related gene expression was quantified using SYBR Green chemistry 
(Applied BioSystems, Life technologies) with specific primers (Table 1). The expression was quantified using the 
ΔΔCT method with 18 S RNA/GAPDH as the endogenous control. Minus-reverse transcriptase samples were 
used as negative controls to test for DNA contamination.
Hematoxylin/Eosin (H&E) staining of pancreases. After sacrifice, a part of the pancreas was embed-
ded into Tissue-Plus O.C.T. Compound (Fisher Scientific Co. L.L.C, Pittsburgh, PA) for morphological analysis 
of pancreatic islets and insulitis degree classification. Treated and nontreated pancreas samples were sectioned 
at 10 um. The homogenous pancreatic sections were stained with hematoxylin/eosin (H&E) and slides were ana-
lyzed by optical microscope for histological identification, localization of lymphocytic infiltration and for classi-
fication of the islets with disturbed architecture50.
Western blot. Western blot of the protein expressed by CD4 and CD8 lymphocytes. Untouched CD4 and 
CD8 T cells were isolated from single cell suspensions of mouse peri pancreatic lymph nodes (LN) and spleen (S) 
using CD4/CD8 T cell isolation kit (Miltenyi Biotech, USA). The enriched single positive CD4 or CD8 cells were 
lysed and protein concentration was determined using commercially available BCA protein estimation kit (Pierce 
Biotechnology). Lysate protein (25–50 ug) was resolved over 8% to 14% Tris-glycine polyacrylamide gel and then 
transferred onto the nitrocellulose membrane. The blot was blocked with 5% nonfat dry milk/3% bovine serum 
albumin (BSA) and further incubated with primary antibodies against mice DHPS (Cat#ab202133, Abcam, 
Cambridge, United Kingdom), Hypusinated elF5A (Cat#ABS1064, Millipore Sigma, Burlington, MA), elF5A 
(Cat#ab137561, Abcam, Cambridge, United Kingdom) and α/β-Tubulin (Cat#2148 S, Cell Signaling, Danvers, 
MA). The blots were washed with washing buffer and further incubated with horseradish peroxidase-labeled sec-
ondary antibodies (Amersham Life Sciences, Little Chalfont, United Kingdom). The intensities of the blots were 
detected by chemiluminescence using an enhanced chemiluminescence kit (Amersham Life Science) followed by 
autoradiography. For every immunoblot, equal concentration and loading volume were confirmed by stripping 
the blot and re-incubation with Tubulin antibody. The densities of the proteins were quantified by using Image J 
software (NIH, USA). The density of expressed proteins was normalized by dividing the density of tubulin of the 
same sample. The data were statistically analyzed in the SAS 9.3 software.
Statistical analysis. Data for glucose, insulin, flow cytometry, real-time expression profile, cytokines and 
western blot were tested for normality by Kolmogorov-Smirnov test and transformed to natural logarithms or 









Mouse total XBP-1_F TGGCCGGGTCTGCTGAGTCCG
Mouse total XBP-1_R GTCCATGGGAAGATGTTCTGG;
Mouse spliced XBP-1_F CTGAGTCCGAATCAGGTGCAG
(original CAG was mutated to AAT to reduce background signal from unspliced XBP-1)
Mouse spliced XBP-1_R GTCCATGGGAAGATGTTCTGG
Mouse 18S_RNA_F CGCCGCTAGAGGTGAAATTCT
Mouse 18S_RNA_R CGAACCTCCGACTTTCGTTC
Mouse eIF5A_ F1 CCCAACATCAAACGGAATGAC (8)
Mouse eIF5A_ R1 GCAGACGAAGGTCCTCTCGTA (8)
Table 1. Quantitative real time PCR primers for ER stress genes.
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expression profile data, anti-GAD65 antibody measurement data, insulin and glucose tolerance test data were 
statistically analyzed by SAS MIXED procedure (version 9.3, SAS Institute, Inc., Cary NC, USA). Analyses were 
done by a 2 × 2 factorial ANOVA for the factors of group and gender for the main effects of group, gender and 
their interaction. When a significant main effect or interaction were detected, Student’s unpaired t-tests were 
used to determine differences in means between two groups or between two genders. For glucose and insulin 
Figure 1. Effect of GC7 treatment: (A) Experimental Design Scheme, (B) elF5A mRNA expression, (C) Mouse 
body weight (gm) and (D) Fasting blood glucose (mg/dl) (bar graph) (n = 6–8 per group). Intraperitoneal 
administration of GC7 significantly reduced the elF5A mRNA expression in the treated groups (n = 4–6 per 
group). Administration of GC7 reduced the fasting blood glucose but the effect was significant only in the male 
treated group. Statistical significance was determined at P < 0.05. Lowercase letters (a–c) identify significant 
differences among the groups. (E) Glucose tolerance test (GTT) in male and female GC7 treated and nontreated 
groups at the 26th week. Males had significantly (*) lower blood glucose at 30 and 90 min. and approaching 
significance (#) at 120 and 150 min. time points (E) as compared to nontreated male, whereas, females showed 
significant differences (*) only at 30 and 60 min. time points as compared to nontreated females. (F) Glucose-
stimulated insulin secretion assay (GTT Insulin). Note that the increase in insulin secretion was observed in 
both male and female treated groups (n = 6–8 per group). (G, H) Pancreatic frozen sections were stained with 
hematoxylin/eosin (H&E) for histological identification and localization of lymphocytic infiltration. Treated 
mice pancreases have a higher degree of infiltration with partially digested islet architecture (G) whereas, in 
the nontreated group, the pancreases were small with digested islet architecture (H). Note: Treated group have 
a significantly higher CD8 count in the pancreas as compared to nontreated group irrespective of gender bias 
(Fig. 2). Gr indicates group; Gn indicates gender. Statistical significance was determined at P < 0.05. Lowercase 
letters (a–c) identify significant differences among the groups.
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concentrations after GTT test in both treated and nontreated groups, analysis was done separately for male and 
female mice with a two-way ANOVA for main effects of treatment, time and their interaction. The significant 
main effects were further tested to locate the difference in means by least significant difference test (for differ-
ence among time points) and Student’s unpaired t-tests (for difference between two treatments). The statistical 
significance threshold was at p ≤ 0.05. Probabilities between p > 0.05 and p ≤ 0.10 were regarded as approaching 
significance. Data were presented as the mean ± SEM.
Results
elF5A inhibition delays onset of diabetes by altering the immune response. Previously, we have 
shown a gender bias in the expression of elF5A in the pancreas of our humanized mice44. In the present study, we 
again confirmed the biased elF5A expression and that the GC7 treatment significantly inhibited elF5A expression 
in both males and females (Fig. 1B). No significant difference was observed in the average body weight between 
Figure 2. Effect of GC7 treatment on CD3, CD4 and CD8 cells. CD3 (A), CD4 (B) and CD8 (C) cells at 
inguinal lymph nodes (IGLN), pancreas (PN), peri-pancreatic lymph nodes (PPLN), and spleen (SP) in GC7 
treated and nontreated male and female mice (n = 4–6 per group) are shown. CD3 and CD4 cells percentage 
were lower in the PN of treated mice whereas, CD8 count was significantly higher in the PN of treated mice. 
Gr indicates group; Gn indicates gender. Statistical significance determined at P < 0.05. Lowercase letters (a–c) 
identify significant differences among the groups. Means with different superscript (* or #) have an approaching 
difference (P = 0.06 to P < 0.1) among the groups or genders.
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Figure 3. (A) Representative flow cytometry analysis (dot plots) gated for CD4 positive T cells and further 
analyzed for FOXP3 and CD25 (contour plots) of Inguinal lymph nodes (IGLN), Peri-pancreatic lymph nodes 
(PPLN), Pancreas (PN) and Spleen (SP) in GC7 treated and nontreated mice. (B) Effect of GC7 treatment 
on Treg cells. Statistical differences (bar graphs) of Treg population are shown. Note that the Treg cells were 
significantly increased in all treated groups and the difference became more significant closer to the pancreas 
(PPLN and PN) (n = 4–6 per group). (C) Effect of GC7 treatment on Th1-cell population (CD3 + CD4 + IFNγ), 
(bar graphs) (n = 6–8 per group). Note that the Th1 cells were significantly reduced in treated groups and 
the reduction becomes more significant at PPLN, PN and SP. (D) Effect of GC7 treatment on Th17 cells 
(CD3 + CD4 + IL17). Statistical differences (bar graphs) of Th17 cells in treated and nontreated mice (n = 6–8 
per group) are shown. Note that Th17 cells were significantly reduced in treated groups and the difference 
becomes more significant closer to the pancreas (PPLN and PN). (E) Effect of GC7 treatment on antigen-
specific cytotoxic CD8 T cells (CTLs) (CD3 + CD8 + IFNγ). Statistical differences (bar graphs) of CTLs cells 
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the treated and nontreated groups throughout the experimental period (Fig. 1C). Average fasting blood glucose 
level was lower in GC7 treated group than in the nontreated group with a significant difference only in males 
(Fig. 1D). GTT at 26 weeks of age showed males had significantly (P < 0.05) lower blood glucose at 30 and 90 min. 
and approaching significant (P = 0.06 to P < 0.1) lower blood glucose at 120 and 150 min. time points (Fig. 1E). 
In contrast, females in the treated group showed lower (P < 0.05) levels only at 30 and 60 min. time points as 
compared to nontreated females.
Insulin release from beta cells is a biphasic response involving a first rapid phase of exocytosis of available 
insulin granules, and a second sustained phase of production and release in response to glucose signaling52. In 
the present study, GSIS showed a differential response based on gender. Males show higher insulin release in the 
first phase (0–10 min) whereas the females showed higher release in the second phase (10–30 min) (Fig. 1F). The 
elF5A inhibition improved the first phase of insulin release in males and the second phase of insulin release in 
females.
Pancreatic frozen sections were stained with hematoxylin/eosin (H&E) for histological identification and 
localization of islets and lymphocytic infiltrates. We observed an improved effect of GC7 treatment on islet archi-
tecture. In the treated group, islets were fully infiltrated but with less disrupted architecture (Fig. 1G); whereas in 
the nontreated group the islets were small with a completely disrupted architecture (Fig. 1H).
Immune resetting in the pancreatic microenvironment following elF5A inhibition. Immune T 
cell profiling of most lymphoid organs of diabetic mice [inguinal lymph nodes (IGLN), peri-pancreatic lymph 
nodes (PPLN) and spleen] are known to be rich in both CD4 and CD8 T cells, whereas the pancreas is mostly 
infiltrated by CD8 T cells (Fig. 2C). The CD8:CD4 ratios in the screened lymphoid organs ranged 4:1 to 3:1 in 
the IGLN, PPLN and spleen whereas there was a huge disparity in the pancreas. In mice and human pancreas’ of 
diabetic individuals, CD4 T cells account for only 2–3% while CD8 T cells account for 80–90% of the total CD3 
positive cells. Coppieters et al. have reported a similar observation in humans37, where it has been demonstrated 
that “autoimmune, islet-reactive CD8 T cell species infiltrated islets from individuals with recent-onset and long-
standing T1D”.
elF5A inhibition reduced the CD4 T cell population. The spleen showed no significant reduction, whereas 
IGLN and PPLN showed some reduction, the pancreas of the female mice showed a significant reduction, and in 
the pancreas of the male mice the effects were approaching significance (Fig. 2B). The effect of elF5A inhibition 
on CD8 T cells was minimal at IGLN and SP. Interestingly in PPLN, CD8 T cells reduced marginally, whereas in 
PN it increased significantly (Fig. 2C).
elF5A inhibition enriches Treg population. Previously, we have demonstrated that elF5A inhibition 
improves the Treg population in the pancreas’ of type 1 diabetic mice44. Here, we analyzed in more detail the 
Treg response in and around the pancreas after elF5A inhibition (Fig. 3A, B). We observed that the enrichment 
of Tregs was not only limited to the pancreas but are also significantly present in the IGLN, PPLN and spleen 
(Fig. 3A, B). In males, elF5A inhibition enriched Tregs in all lymphoid organs and the enrichment was more sig-
nificant closer to the pancreas, whereas in females the significant enrichment (p < 0.05) of Treg population was 
observed only in pancreas following elF5A inhibition.
elF5A inhibition reduces Th1 and Th17 cells. The inflammatory nature of TID suggests that Th1 and 
Th17 cells should be elevated; we thus measured the effect of elF5A inhibition on IFNγ producing CD4 T cells 
(Th1) and IL17 producing CD4 T cells (Th17). In the nontreated group, we observed the infiltration of both 
cell types in the pancreas and elevated numbers in IGLN, PPLN and spleen. In the treated group, inhibition of 
elF5A significantly reduced the frequency of Th1 cells at all lymphoid organ sites, especially closer to the pancreas 
(Fig. 3C). The reduction in Th17 cell numbers was highly significant, approaching 60%, in PPLN and pancreas 
but was not-significant in IGLN and spleen (Fig. 3D) in comparison to the nontreated group. Interestingly, the 
reduction was more pronounced in males as compared to females, in accordance with their elF5A expression 
(Fig. 1B). This observation also implies that most of the islet-specific Th17 cell recruitment may have occurred at 
PPLN and pancreas level (Fig. 1G).
elF5A inhibition has least effect on CTLs. CTLs are the main effector cells executing the destruction of 
β-cells. We show here that in our diabetic mice, IFNγ producing CD8 T cells are the main immune subset present 
in the pancreas and the sentinel lymph nodes (PPLN, IGLN) (Fig. 3E). This observation supports that T1D in 
our mouse model mimics T1D of humans3–5. Following the elF5A inhibition, we did not observe any significant 
reduction in the CTL population in all of the lymphoid organs screened.
Differential expression of elF5A, hypusinated elF5A and DHPS in CD4 and CD8 T cells. CD4 
and CD8 lymphocytes were isolated from peri-pancreatic lymph nodes (LN) and the spleen (S). The protein blot 
of DHPS, hypusinated elF5A and elF5A proteins were compared and results revealed that DHPS, hypusinated 
(n = 6–8 per group) are shown. Note that CTLs cells were reduced in treated groups and that the difference only 
becomes apparent at PPLN and PN but no overall effect was observed. Gr indicates group; Gn indicates gender. 
Statistical significance was determined at P < 0.05. Lowercase letters (a–c) identify significant differences among 
the groups. Means with different superscript (* or #) have an approaching to significance difference (P = 0.06 to 
P < 0.1) among groups or genders.
www.nature.com/scientificreports/
8Scientific RepoRts |          (2019) 9:1533  | https://doi.org/10.1038/s41598-018-38341-5
elF5A and elF5A were expressed in higher concentrations in CD4 single cell lysates as compared to CD8 single 
cell lysates from LN. However, we noticed the opposite results in splenic single cell lysates of CD4 and CD8 cells 
(Fig. 4A, B). Interestingly, we also observed a significantly higher expression (P < 0.05) of elF5A protein in the 
CD4 cell lysate as compared to CD8 cell lysate of male LN (Fig. 4B). Higher expression of elF5A in CD4 as com-
pared to CD8 T cells has been reported in BioGPS (http://biogps.org/#goto=genereport&id=1984).
elF5A inhibition changes the tissue-specific T cell ratios. The outcome of autoimmunity usually 
depends on the balance between the pro-inflammatory and anti-inflammatory signals at the specific tissue 
sites. Thus, we determined the effect of eIF5A inhibition on the ratios of effector T cell populations in different 
Figure 4. Differential expression of elF5A, Hypusinated elF5A and DHPS in CD4 and CD8 T cells.  
(A) Western blot of CD4 and CD8 lymphocytes isolated from pancreatic lymph nodes (LN) and spleen (S).  
All the bands present in male/female samples were extracted from the respective single blot with the same 
exposure time. (B) DHPS, Hypusine, and elF5A were less expressed in CD8 T cells of pancreatic lymph nodes 
whereas the expression of these proteins were higher at splenic CD8. Note: elF5A protein expression was 
significant (P < 0.05) higher in the CD4 cell lysate of male LN.
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lymphoid organs of the treated group. The analysis revealed that the Treg/Th17 ratios were increased significantly 
in the pancreas, IGLN and PPLN of males, whereas the effect on the ratio in these tissues was non-significant 
in females (Fig. 5A). No difference was observed in Treg/Th17 ratio in the spleen of either male or female mice. 
Figure 5. (A) Effect of GC7 treatment on Treg/Th17 ratio. Treg/Th17 ratios at inguinal lymph nodes (IGLN), 
Pancreas (PN), Peri-pancreatic lymph nodes (PPLN), and Spleen (SP) in GC7 treated and nontreated male and 
female mice (n = 4–6 per group) are shown. Note that the difference in Treg/Th17 ratios became significant 
closer to the pancreas (PPLN and PN). (B) Effect of GC7 treatment on Treg/Th1 ratio. Treg/Th1 ratios at IGLN, 
PN, PPLN, and SP in GC7 treated and nontreated male and female mice (n = 4–6 per group) are shown. Treg/
Th1 ratio was higher in the IGLN, PPLN, PN and SP of male treated mice, whereas in female Treg/Th1 ratio 
was higher at PN and SP. (C) Effect of GC7 treatment on Th1 and Th17 cells plasticity. Upper panel represents 
a contour plot of CD4 + T cells co-expressing IL-17 and IFNγ at IGLN, PPLN, PN and SP. In males, the 
IFNγ + IL17 + CD4 cells were significantly increased in IGLN, PPLN and PN whereas in females the significant 
increase was observed only in SP and IGLN. (D) Effect of GC7 treatment on CD8/CD4 ratios at IGLN, PN, 
PPLN, and SP; CD8/CD4 ratios were increased in the pancreas, IGLN and spleen whereas the ratio decreased in 
PPLN of both males and females. Note: This decrease in ratio implies that eIF5A inhibition reduced the CD8 T 
cell count in the PPLN only, site of recruitment of CD8 T cells in T1D (n = 4–6 per group).
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The ratios of Treg/Th1 in males were significantly elevated in pancreas, IGLN and PPLN, but were trending 
significantly higher in the spleen (Fig. 5B). In females, the Treg/Th1 ratios showed significant differences only in 
the pancreas and spleen but no significant differences were observed in IGLN and PPLN.
Th17 cells are plastic and have been described to acquire Th1 phenotypes. Thus, we evaluated the effect 
of elF5A inhibition on the population of CD4+ T cells co-expressing IL17 and IFNγ, a transitionary cell type 
between Th17 and Th1 cells. In males, the IFNγ + IL17 + CD4 cells were significantly increased in IGLN, PPLN 
and pancreas following eIF5A inhibition, whereas in females the significant increase was observed in the spleen 
and IGLN only (Fig. 5C). This observation suggests that the eIF5A inhibition may influence the plasticity of T 
helper cells.
We further compared the CD8/CD4 ratio in different lymphoid organs. The analysis revealed that the ratios 
were increased in the pancreas, IGLN, and spleen following elF5A inhibition, whereas decreased in PPLN of both 
males and females (Fig. 5D). This decrease in ratio implies that the eIF5A inhibition reduced the CD8 T cell count 
(Fig. 2C) or increased the CD4 T cell subsets (Tregs, Fig. 3B) in the PPLN (site of activation and proliferation). 
Overall this data emphasizes the impact on the immunological outcome of eIF5A inhibition which seems to 
occur both at the sites of activation and execution.
Figure 6. (A) Effect of GC7 treatment on Mice serum concentration of IL-21 (B) IL-17 in GC7 treated male 
and female mice. Note that the IL-17 concentration directly correlates with the IL-21 serum concentration. 
Note that serum IL21 concentration was reduced to approaching significance in treated male and serum 
IL17 concentration was reduced to approaching significance in the treated female group. (C) Effect of GC7 
treatment on anti-GAD65 antibody production. Administration of GC7 significantly reduced the GAD65 
antibody production in the treated group (n = 4–6 per group). Note that elF5A expression directly correlates 
with the severity of T1D and GAD65 antibody production. (D) Effect of GC7 treatment on pancreatic beta cell 
functionality. Administration of GC7 significantly increased the functionality of beta cells (n = 4–6 per group). 
The total insulin production was significantly increased in the male treated group. Gr indicates group; Gn 
indicates gender. Statistical significance was determined at P < 0.05. Lowercase letters (a–c) identify significant 
differences among the groups. Means with different superscript (* or #) have an approaching to significance 
difference (P = 0.06 to P < 0.1) among the groups.
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Effect of elF5A inhibition on serology. Chronicity of T1D correlates with IL17 and IL21 concentra-
tions53; therefore, we measured the serum cytokine levels in our mice at the end of the experiment. The elF5A 
inhibition reduced serum IL17 and IL21, but the effect was not significant (Fig. 6A, B).
We also measured anti-GAD65 antibodies in the sera of mice. Serum anti-GAD65 antibodies were detected in 
both groups (treated/nontreated) and their titers correlated with the serum glucose levels and GTT. Inhibition of 
elF5A significantly reduced the antibody titer both in males and females (Fig. 6C) and this reduction correlated 
with the delay of diabetes onset/progression.
elF5A inhibition improves the total pancreatic insulin content. We have shown a gender bias in 
the pancreatic elF5A expression in our humanized mice (Fig. 1B). A similar kind of gender bias was also seen in 
the total insulin content of the pancreas and the elF5A inhibition significantly increased the pancreatic insulin 
content in the male treated group only (Fig. 6D).
elF5A inhibition reduces the ER stress gene profile in the pancreas. A pro-inflammatory bias in 
the pancreatic microenvironment induces ER stress in β-cells. We, therefore, studied the effect of eIF5A inhibi-
tion on the expression of ER stress-related genes in the pancreas. Our analysis revealed that elF5A inhibition in 
the treated group significantly reduced the expression of BiP, Ero1l, CHOP, total XBP-1 and spliced XBP-1s in 
both genders compared to control group, but the effects were more pronounced in males. The total and spliced 
XBP 1 which were highly expressed in nontreated group, showed a huge decrease after eIF5A inhibition in both 
genders (Fig. 7D, E). Expression of BiP, CHOP and Ero1l was also high in nontreated diabetic mice but the 
expression was reduced significantly following the eIF5A inhibition (Fig. 7A–C).
Discussion
In this study, we were able to delineate the role of autoreactive T helper cells and CTLs in the mediation of T1D 
as a result of a specific intervention. The eIF5A inhibition reduced the pro-inflammatory bias in the pancreatic 
microenvironment by reducing Th1 and Th17 cells, and enriching Tregs. This enrichment helped to improve the 
functionality of β-cells in terms of insulin release and reducing ER stress; however, it did not abrogate the CTL 
mediated destruction of β-cells. Overall, our study illustrates that interventions targeting only the T helper cell 
Figure 7. Effect of GC7 treatment on markers of ER stress in islet microenvironment. Administration of GC7 
significantly reduced the expression of ER stress genes (A) BiP, (B) Ero1l, (C) CHOP, (D) total XBP-1 and  
(E) spliced XBP-1s in the pancreatic islet microenvironment of treated mice (n = 4–6 per group). Gr: group;  
Gn: gender. Statistical significance determined at P < 0.05. Lowercase letters (a–c) identify significant 
differences among the groups.
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subsets may not be able to revert T1D (at least in our humanized mouse model) until the interventions to restrain 
autoreactive CTLs in the islet microenvironment are combined. This may also hold true for interventions for 
human T1D.
eIF5A is a small, highly conserved protein necessary for translational elongation of specific mRNA transcripts, 
especially of proteins involved in G1 to S cell cycle transition54 and cytotoxic stress response55. Few studies have 
demonstrated eIF5A’s immunological role56,57. Others have demonstrated that hypusinated eIF5A is essential for 
the expression of CD83 in DCs correlating to their maturation58. In the context of T1D, eIF5A participates in the 
inflammatory cascade leading to β cell dysfunction during the development of diabetes in NOD mice43. Most 
importantly, Colvin et al. previously demonstrated that eIF5A inhibition by GC7 administration in NOD mice 
causes selective reduction of diabetogenic Th1 cells in the pancreatic lymph nodes45.
This current study and our previous study44 demonstrated that eIF5A inhibition by GC7 has a more profound 
effect on T helper cell compartments (Th1, Th17 and Tregs) as compared to the CTL compartment in our human-
ized mouse model of T1D.
The novelty of our findings can be enumerated as follows: (1) We revealed that the plasticity of T helper cells 
seems to be ideal in providing the pro-inflammatory bias for induction of T1D; and that plasticity gives room 
to manage T1D in the early stage of the disease. (2) We demonstrated that inhibition of elF5A helps enrich 
Treg/Th17 ratios and is a positive development in delaying the onset of T1D. (3) We proved that reduction in 
pro-inflammatory cytokines reduces ER stress in secretory endocrine cells of the pancreas, which in turn sustains 
insulin production. (4) We provided evidence that by reducing the pro-inflammatory cytokine milieu late in the 
disease, T1D cannot be reverted unless antigen-specific CTLs are halted.
The differential gender bias of elF5A expression may explain the overall lower response in female mice to 
the elF5A inhibition. This bias was also seen in the total insulin content of the pancreas (Fig. 6D). The elF5A 
inhibition showed a significant increase in the pancreatic insulin in males only. The gender bias in incidence and 
aggressiveness of T1D is also observed in humans where global male: female incidence ratio is 1.4759, in contrast 
with that observed on NOD mice60. Differential expression of elF5A in CD4 and CD8 T cells has been reported in 
BioGPS and similarly demonstrated in our western blot results (Fig. 4B).
Inhibition of elF5A reduces the pro-inflammatory bias by reducing the number of antigen-specific Th1 cells 
in the target lymphoid organs. In our mice, the effect of inhibition was more pronounced closer to the pancreas. 
The reduction in Th1 cells may be due to a change in the phenotype of T helper cells to Tregs, or may be due to 
subsequent events that create other T-helper cell subsets61. It has been also reported that Treg cells can be con-
verted into IL17 expressing CD4 cells in a proinflammatory cytokine milieu38. Specific transcription factors have 
been identified which orchestrate the differentiation program of T helper subsets; mainly TGF-β and IL6 are 
important for Th17 differentiation; whereas TGF-β, retinoic acid and IL-2 dominance is prerequisite for iTreg 
cells differentiation62. Th1 cells play an important role in priming CTLs as it has been demonstrated that Th1 cells 
could acquire major histocompatibility complex/peptide I complexes and costimulatory molecules by dendritic 
cell activation, and further stimulate naïve CD8+ T cell proliferation and activation of CTLs63. Increasing levels 
of Th1 was shown to correlate with the progression of diabetes in NOD mice64. Inhibition of elF5A in the treated 
group reduced the Th1 cells in and around the pancreas (PPLN and PN) in our humanized mouse model. The 
inhibition of elF5A significantly reduced the Th1 response at all sites but the effects were more significant closer 
to the pancreas.
In our humanized mouse model, upon GAD65 immune response induction, Th17 cells become abundantly 
present in the pancreatic microenvironment as seen in the nontreated group. Inhibition of elF5A in the treated 
group significantly reduced the population of Th17 cells and the reduction in Th17 cells likely helped Treg cells 
proliferate. Alternatively, inhibition of elF5A may have induced plasticity of Th17 cells towards Treg cells61. The 
effect of elF5A inhibition on the reduction of Th17 cells was more pronounced at the IGLN, PPLN and PN of 
male as compared to female mice. Whereas inhibition of elF5A enriched the Treg cells in the pancreatic microen-
vironment, the enrichment was significantly higher in lymphoid organs of both males and females in the treated 
group. Our findings suggest that Treg/Th17 ratio determines the fate of beta cells in our mouse model. Here we 
further showed that inhibition of elF5A reduced the Th17 cell population and improved the Treg population in 
the pancreatic microenvironment. The increment in the Treg/Th17 ratio after elF5A inhibition directly correlated 
with the beta cell functionality and insulin production.
Differentiation of CD4 T cells to different subsets of T cells are cytokines milieu dependent. Here we have 
modulated the cytokines milieu by inhibiting elF5A which may have had a role in inducing plasticity of different 
T helper subsets towards Tregs. However, our findings raise the question of whether a reduction of inflammatory 
cells can abrogate ongoing T1D due to auto-antigen specific CTLs. We have dissected the role of immune cells in 
the pathogenesis of the disease; by inhibiting elF5A, we were able to reduce the pro-inflammatory bias. The over-
all effect was that elF5A inhibition improved the functionality of beta cells in terms of GTT and total pancreatic 
insulin content. However, reducing the pro-inflammatory milieu was unable to change the fate of T1D outcome. 
Our findings suggest that autoreactive CTLs should also be a target of immune based treatment of T1D.
CD8/CD4 T-cell ratio represents an index of immunological balance between T-cytotoxic cells and 
T-helper65,66. In the case of children with diabetes, positive for complement fixing islet cell antibodies (CF-ICA), 
there was a consistent increase in the CD8/CD4 lymphocyte ratio before the clinical onset of the T1D66. Therefore, 
increments in the CD8/CD4 ratio appear to be a marker of T1D progression. In our study, we observed that 
elF5A inhibition had an opposite effect on all the lymphoid organs like IGLN, PN and Spleen as CD4 count were 
reduced in these three organs (Figs 2 and 4D), whereas elF5A inhibition induced a reduction in the CD8/CD4 
ratio at PPLN. This reduction is important because this is the site of CD8/CTLs proliferation and licensing as 
evident by the histochemistry of the pancreas in the treated group (Fig. 1G).
IL21 is mainly secreted by Th17 cells in autoimmune diseases, and has a major role in driving terminal B-cell 
differentiation to plasma cells while having a major stimulatory effect on antigen-specific autoreactive T-cells. It 
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has been shown that IL21 production correlates with increased numbers of Th17 cells and decreased numbers 
of Treg cells in patients with SLE67. It has also been reported that Th17 cells could be involved in the control of 
the local and systemic inflammatory responses in chronic emphysema by upregulating the CD8+ cytotoxic T-cell 
function68. Conversely, we show that inhibition of elF5A marginally reduces the CTLs pool at PPLN in our T1D 
model (Fig. 3E). This effect may be because of reduction in serum IL21 and IL17 cytokines, which is important 
for the activation and maintenance of CTLs68–71. Along with the promotion of CD8 cytotoxic responses, it has 
been shown that in emphysematous mice, Th17 and IL21 cells are positively correlated with their lesions68. Here 
we want to state that inhibition of elF5A reduces the IL21 expression in male (Fig. 6A) and IL17 expression in 
both the genders (Fig. 6B), which may be due to a change in pro-inflammatory bias, and may help in marginal 
reduction of CTLs in peri-pancreatic lymph nodes of mice (Fig. 3E).
Pancreatic β-cell endoplasmic reticulum (ER) shows an adaptive response even in normal physiological con-
ditions. Both acute (1–3 hours) and chronic (≥24 hours) exposure to high glucose (≥16.7 mM) have been shown 
to induce ER stress in mice72. However, in the case of T1D, the ER stress level is exaggerated by the immune 
cells infiltrating the pancreatic islets, secreting various pro-inflammatory cytokines, which directly affect the 
islet microenvironment and exacerbate ER stress. When studying the effect of cytokines on ER stress response, 
isolation of individual islets is not suitable because the process itself exacerbates ER stress73. To manage inflamma-
tion, metabolic, and other stressful adverse conditions, the organelle has evolved an adaptive response. Here, the 
effect of inflammation on ER stress was studied by measuring the expression of the ER stress genes in the whole 
pancreas (Fig. 7). When the ER is loaded with an excess of protein folding work, the UPR signaling pathways will 
be activated. In the first line of defense, stressed cells try to survive through the arrest of transient translation of 
nascent proteins. Secondly, the export of misfolded proteins for degradation known as ER-associated degradation 
(ERAD). In the third stage, ER increases the folding capacity of the affected ER by induction of chaperones and 
folding enzymes. Prolonged ER stress impairs homeostasis and induces apoptosis74,75. X box-binding protein 
(XBP)1 overproduction is part of the ER stress response and overexpression increases the aggressiveness of the 
autoimmune diseases76,77. Similar patterns have been observed in our mouse model (Fig. 6C, D). Basal expression 
of elF5A is essential for ER-to-Golgi vesicle transport78,79, whereas DHS promotes the differentiation and pro-
liferation of T Helper Type 1 (Th1) Cells in T1D45. Inhibition of elF5A using DHS inhibitor “GC7” significantly 
reduced the XBP-1 and spliced XBP-1s expression in the pancreas of our mouse model (Fig. 7D, E). Spliced XBP-1 
helps the ER in compensating mild to moderate ER stress80. A correlation of XBP-1 gene expression level with 
antibody production has also been shown80. The expression of XBP-1 protein is required for the transcription of a 
subset of class II major histocompatibility genes77. XBP-1, in turn, controls the expression of IL6 which promotes 
plasma cell growth and production of immunoglobulins81. Our results show that XBP-1 gene expression is cor-
related with the anti-GAD65 antibody production, which was reduced significantly with the inhibition of elF5A 
(Fig. 6C, D). BiPs or HSPA5 is a 78 kDa ER chaperone protein, serving as an ER stress sensor. Under oxidative 
and functional stress, BiP overexpressed and compensates ER stress (adaptive phase). According to the results, 
elF5A inhibition significantly reduced BiP in both male and female mice in the treated group and reduced the ER 
stress level in the pancreas (Fig. 7A). Prolonged ER stress impairs homeostasis to compensate for the workload 
of the UPR. Endoplasmic reticulum overexpresses CHOP, a transcription factor belonging to the bZIP family 
(alarm/apoptosis phase). Upon activation, CHOP suppresses anti-apoptotic protein BCL-2, which may induce 
beta cell apoptosis82. Here we have shown that inhibition of elF5A significantly reduces CHOP expression in both 
male and female mice in the treated group, but the effect was more significant in males (Fig. 7C). Therefore, inhi-
bition of elF5A may protect the beta cells from ER stress mediated apoptosis, as evidenced by immunohistochem-
istry of treated mice pancreas (Fig. 1G). As mentioned, the pancreatic islet microenvironment of our T1D mouse 
model was infiltrated with Th1, Th17 and CTLs cells, which lead to high concentrations of pro-inflammatory 
cytokines and IL17, which likely acerbated generation of ER stress in islet/beta cells. This may have lead to secre-
tion of reactive oxygen species, which is involved in directly inducing ER stress to adjacent islets. We show here 
that elF5a gene expression was proportional to ER stress gene expression, anti-GAD 65 antibody production, and 
inversely proportional to the Treg/Th17 ratio. Inhibition of elF5A in the treated group significantly reduced the 
ER stress gene expression as well as the elF5a expression in the pancreas of mice.
Conclusions
Altogether, our results show for the first time, that downregulation of eIF5A through inhibition of DHS favors the 
reversal of the Th1 mediated described processes but minimally affects CTLs. Inhibition of elF5A increases the 
Treg/Th17 ratio, reduces anti-GAD65 antibody production and islet/β-cell ER stress that leads to improvement in 
the endocrine pancreas functionality in our humanized model of T1D. Diabetes onset is delayed but progression 
is inevitable.
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